Trustmark National Bank Trust Department Sells 3,848 Shares of GSK plc (NYSE:GSK)

Trustmark National Bank Trust Department lowered its holdings in shares of GSK plc (NYSE:GSK) by 7.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,793 shares of the pharmaceutical company’s stock after selling 3,848 shares during the quarter. Trustmark National Bank Trust Department’s holdings in GSK were worth $1,995,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Eastern Bank bought a new position in shares of GSK in the 3rd quarter valued at about $26,000. Concord Wealth Partners lifted its stake in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK during the 2nd quarter valued at approximately $37,000. Fortitude Family Office LLC purchased a new stake in GSK during the 3rd quarter valued at $42,000. Finally, PrairieView Partners LLC bought a new stake in GSK in the second quarter worth $47,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Down 0.3 %

NYSE:GSK opened at $33.36 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 1-year low of $32.83 and a 1-year high of $45.92. The company has a 50-day moving average of $38.46 and a 200 day moving average of $40.49. The firm has a market cap of $69.14 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.71%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 99.35%.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This represents a 19.97 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on GSK shares. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.